This Could Be Key to Pfizer's Turnaround in 2026

Did you know that in just the past three years, healthcare giant Pfizer (NYSE: PFE) has lost approximately half its value? The stock surged during the pandemic as its COVID-19 vaccine and pill enabled it to generate record numbers. But in recent years, concerns about future growth and patent cliffs have weighed on its valuation.The company has been working on trying to enhance its growth opportunities via acquisitions, but that hasn't been sufficient to turn things around for the stock -- not yet, anyway. However, there's one potentially lucrative growth opportunity that Pfizer's focusing on that could change things and drastically improve the stock's trajectory, perhaps as early as this year, and that's GLP-1 drugs.Image source: Getty Images.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool